NCT01909934 2025-09-19Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell LymphomaTakedaPhase 4 Completed50 enrolled 22 charts
NCT01703949 2025-06-11Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ LymphomaUniversity of WashingtonPhase 2 Active not recruiting28 enrolled